反应详情

温度

100 °C

A suspension methyl 2-(4-bromo-1-(4-chlorophenyl)-3-methylnaphthalen-2-yl)-2-tert-butoxyacetate (10.5 mg, 22.1 μmol), [1H]pyrimidin-2-one-5-yl-boronic acid (25 mg, 0.11 mmol), PdCl2(dppf) (3.2 mg, 4.4 μmol), K2CO3 (46 mg, 0.33 mmol), PhMe (500 μL), EtOH (absolute, 250 μL), and H2O (250 μL) was heated to 100° C. for 30 min, but conversion was poor. The reaction was treated with glacial AcOH (60 μL, 1.05 mmol) and KF (40 mg, 0.688 mmol). More PdCl2(dppf) (3.2 mg, 4.4 μmol) and [1H]pyrimidin-2-one-5-yl-boronic acid (7 mg, 30 μmol) were added and the reaction was heated to 100° C. After 2 h, the reaction was added to H2O (15 mL) and glacial AcOH (0.2 mL). The system was extracted with EtOAc (3×10 mL). Combined organic phases were dried (Na2SO4), filtered, and concentrated. The crude material was treated with THF (750 μL), EtOH (absolute, 750 μL), H2O (500 μL), and LiOH monohydrate (50 mg 1.2 mmol). The suspension was heated to 100° C. for 30 min. The reaction was cooled to 23° C., filtered through a 0.45 micron filter, and directly purified by reverse phase HPLC (Gemini, 5 to 100% ACN/H2O+0.1% TFA). The product-containing fractions were combined and lyophilized, giving the title compound (parent form) (3.8 mg, 36% over 2 steps). 1H-NMR: (400 MHz, DMSO-d6): δ 12.8 (s, broad, 1H), 8.29 (app. s, broad, 1H), 7.75-7.68 (m, 2H), 7.58-7.44 (m, 4H), 7.43-7.38 (m, 2H), 7.25 (d, J=8.2 Hz, 1H), 5.12 (s, 1H), 2.38 (s, 3H), 0.96 (s, 9H). LCMS-ESI+ (m/z): [M+H]+ calcd for C27H26ClN2O4: 477.2; Found: 477.2.

1. extractionThe system was extracted with EtOAc (3×10 mL)
2. dry with materialCombined organic phases were dried (Na2SO4)
3. filtrationfiltered
4. concentrationconcentrated
5. temperatureThe suspension was heated to 100° C. for 30 min
6. temperatureThe reaction was cooled to 23° C.
7. filtrationfiltered through a 0.45 micron
8. filtrationfilter
9. customdirectly purified by reverse phase HPLC (Gemini, 5 to 100% ACN/H2O+0.1% TFA)